While the BCR-ABL fusion gene leads to uncontrolled cell growth, when the fusion gene is identified in a patient, CML can be treated successfully with tyrosine kinase inhibitors. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.